Prothena will cut 63% of its workforce and evaluate a “range of business options.” Elsewhere, Zealand revealed data for a ...

In May, the company announced the failure of the monoclonal antibody birtamimab to improve mortality in a phase 3 trial of ...

Prothena Corp shares climbed 5% in after-hours trading on Friday after the company said it expects to reduce its 2025 net ...

Ventyx Biosciences has shared promising top-line results from a phase 2a study of its investigational central nervous system ...

AstraZeneca signed a potential $5 billion research deal with Chinese drugmaker CSPC. Eli Lilly is buying Verve Therapeutics for $1 billion upfront plus a CVR potentially worth another $300 million.

Smith & Wesson Brands reported falling profit and sales as consumers become more cautious. The gunmaker's CEO, Mark Smith, ...